A phase II trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701

Rituximab combined with chemotherapy has improved the survival of previously untreated patients with follicular lymphoma (FL). Nevertheless, many patients neither want nor can tolerate chemotherapy, leading to interest in biological approaches. Epratuzumab is a humanized anti-CD22 monoclonal antibod...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Grant, Barbara W., Jung, Sin-Ho, Johnson, Jeffrey L., Kostakoglu, Lale, His, Eric, Byrd, John C., Jones, Jeffrey, Leonard, John P., Martin, S. Eric, Cheson, Bruce D.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2013
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3828050/
https://ncbi.nlm.nih.gov/pubmed/23922187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28299
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky